Introduction: Intravenous thrombolysis (IT) and mechanical thrombectomy (MT) have significantly changed the clinical outcome of acute ischaemic stroke (AIS). Concerns about possible complications often reduce the use of these treatment options for older patients, preferentially managed with antiplatelet therapy (AT). Aim of this study was to evaluate, in a population of middle-old (75–84 years) and oldest-old (≥ 85 years) subjects, the efficacy and safety of different treatments for AIS (IT, IT + MT, MT or AT), mortality and incidence of serious complications. Patients and methods: All patients aged over 75 years admitted for AIS in two Stroke Units were enrolled. The physician in each case considered all treatment options and chose the bes...
Background and Purpose-Demographic changes will result in a rapid increase of patients age >= 90 ...
Background and Purpose—Intravenous tissue plasminogen activator (tPA) administered within 3 hours of...
BACKGROUND AND PURPOSE: It is unclear whether endovascular therapies for the treatment of AIS are be...
Introduction: Intravenous thrombolysis (IT) and mechanical thrombectomy (MT) have significantly chan...
BACKGROUND: The benefit of intravenous tissue plasminogen activator (tPA) given within 3 h of acute ...
Stroke is a common cause of death and persisting disability worldwide, and thrombolysis with intrave...
The probability to receive intravenous thrombolysis (IVT) for treatment of acute ischemic stroke dec...
Background and Purpose. Intravenous thrombolysis using tissue plasminogen activator is safe and prob...
OBJECTIVE: To explore clinical outcomes in older adults with acute ischemic stroke treated with endo...
Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patient...
BACKGROUND: Acute ischaemic stroke is common in older people. There is one licensed acute treatment,...
Objectives: To evaluate the safety and efficacy of endovascular therapy in elderly adults treated fo...
The incidence of ischemic stroke rises exponentially with age, with a steep increase in the age inte...
BACKGROUND: Intravenous (i.v.) thrombolysis with rt-PA within 3 h from symptom onset is the only app...
Objective: To explore clinical outcomes in older adults with acute ischemic stroke treated with endo...
Background and Purpose-Demographic changes will result in a rapid increase of patients age >= 90 ...
Background and Purpose—Intravenous tissue plasminogen activator (tPA) administered within 3 hours of...
BACKGROUND AND PURPOSE: It is unclear whether endovascular therapies for the treatment of AIS are be...
Introduction: Intravenous thrombolysis (IT) and mechanical thrombectomy (MT) have significantly chan...
BACKGROUND: The benefit of intravenous tissue plasminogen activator (tPA) given within 3 h of acute ...
Stroke is a common cause of death and persisting disability worldwide, and thrombolysis with intrave...
The probability to receive intravenous thrombolysis (IVT) for treatment of acute ischemic stroke dec...
Background and Purpose. Intravenous thrombolysis using tissue plasminogen activator is safe and prob...
OBJECTIVE: To explore clinical outcomes in older adults with acute ischemic stroke treated with endo...
Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patient...
BACKGROUND: Acute ischaemic stroke is common in older people. There is one licensed acute treatment,...
Objectives: To evaluate the safety and efficacy of endovascular therapy in elderly adults treated fo...
The incidence of ischemic stroke rises exponentially with age, with a steep increase in the age inte...
BACKGROUND: Intravenous (i.v.) thrombolysis with rt-PA within 3 h from symptom onset is the only app...
Objective: To explore clinical outcomes in older adults with acute ischemic stroke treated with endo...
Background and Purpose-Demographic changes will result in a rapid increase of patients age >= 90 ...
Background and Purpose—Intravenous tissue plasminogen activator (tPA) administered within 3 hours of...
BACKGROUND AND PURPOSE: It is unclear whether endovascular therapies for the treatment of AIS are be...